Full Prescribing Information
Important Safety Information
Patient Site
Vistogard® is being distributed by BTG Pharmaceuticals as of July 1, 2023. For more details please click here.

DON'T WAIT
TO ACT

Vistogard®* (uridine triacetate) oral granules is the first and only antidote for 5-FU overdose and early-onset, severe or serious 5-FU toxicity

Indication

VISTOGARD® is indicated for the emergency treatment of adult and pediatric patients:

  • Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or
  • Who exhibit early-onset, severe or life- threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.

Limitations of use

  • VISTOGARD® is not recommended for the non-emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs.
  • The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.
*A pyrimidine analog

Don't Wait

Stay alert for early, severe 5-FU or capecitabine toxicity

Vistogard

Don't Wait to Act

These RED FLAGS require immediate attention

Unusually severe side effects 3, 8, 9, 12

Digestive
  • Mucositis (mouth pain, pain on swallowing)
  • Vomiting not well controlled by antiemetics
  • Diarrhea
Blood
  • Leukopenia (WBC ‹3500 or falling rapidly)
  • Neutropenia (ANC ‹1000 cells/µL or falling rapidly)9
  • Thrombocytopenia (‹100,000 platelets/µ or falling rapidly)

CNS and cardiac side
effects 4, 10, 15-18

CNS
  • Altered mental status
  • Cerebellar ataxia
  • Changes in cognition or consciousness
Cardiac
  • Acute cardiomyopathy
  • Chest pain
  • Heart failure
  • Heart attack
  • Irregular heart beat

Red flags developing early (especially during the first or second treatment cycle and appearing within 96 hours of 5-FU or capecitabine administration) should be addressed promptly. 1-3

Vistogard

Dosing

Vistogard

Treating ASAP

Vistogard

Clinical Data

Mechanism of Action

(MOA)

Vistogard

Documented Safety Profile

Vistogard

You are now leaving the patient site.

The section you selected contains information intended for U.S. healthcare professionals only.
Please certify that you are a U.S. healthcare professional by clicking the link below.

Yes, I am a U.S. Healthcare professional No, I am not a U.S. Healthcare professional